A Phase 1, Parallel-group, 3-part, 2-period, Fixed-sequence, Crossover, Open-label, Nonrandomized, Drug-drug Interaction Study to Assess the Pharmacokinetics of CC-92480 (BMS-986348) After Coadministration With Rifampin and Itraconazole, and Pharmacokinetics of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
Latest Information Update: 20 May 2024
At a glance
- Drugs Digoxin (Primary) ; Itraconazole (Primary) ; Mezigdomide (Primary) ; Rifampicin (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 29 Mar 2024 Results assessing Physiologically Based Pharmacokinetic (Pbpk) Modeling to Inform the Design of a Clinical Drug-Drug Interaction presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 18 Apr 2023 Status changed from recruiting to completed.
- 25 Oct 2022 Status changed from not yet recruiting to recruiting.